Goldshield Pays £4M To Settle Price-Fixing Allegations

Law360, New York (June 25, 2007, 12:00 AM EDT) -- Pharmaceutical company Goldshield Group plc has agreed to pay the United Kingdom Department of Health £4 million ($8 million) to settle claims of price-fixing, while two of the company’s executives have stepped down amid allegations of anti-competitive behavior, the company said Friday.

Under the settlement, the DOH agreed to drop civil charges against Goldshield and subsidiaries Goldshield Pharmaceuticals Ltd. and Forley Generics Ltd. The regulator alleged that the companies participated in an anti-competitive scheme while selling their generic version of blood-thinning medication warfarin to the National...
To view the full article, register now.